Remdesivir Hype Doesn’t Align with Science

Remdesivir has recently received 2 huge votes of confidence: a deal to supply the EU with the antiviral, and FDA approval as a COVID-19 treatment.
Both decisions have “baffled” scientists.
The largest remdesivir study so far, from the WHO, showed the drug did nothing to reduce mortality or recovery time.
Yet the FDA didn’t include the WHO study in its review recommending remdesivir’s approval, nor any evidence that it reduces viral load.
With so little data and incredibly high stakes, there’s another big question: Why didn’t the FDA convene its outside expert panel to discuss remdesivir’s merits, as it did last week with vaccines?


Comments +


Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top